Please login to the form below
Chugai
The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Chugai's Japan sales performance.
Gilead, Galapagos dip on mixed ulcerative colitis data
Filgotinib is already under regulatory review in the US, Europe and Japan as a treatment for rheumatoid arthritis, but Gilead and Galapagos will need to extend the use of the drug
Biopharma body welcomes EU-UK free trade agreement docs
The UK seeks an FTA close to those agreed by the EU with Canada or Japan. ... union, and instead is seeking a free trade agreement (FTA) that “approximates very closely those the EU has agreed with Canada or Japan”.
Novartis claims EU approval for SMA gene therapy Zolgensma
Japan in March where it has been given a lower price of around $1.55m dollars.
FDA clears phase 2 COVID-19 trial of ViralClear’s merimepodib
Aside from an emergency use authorisation for remdesivir and hydroxychloroquine/chloroquine in the US and a similar approval for remdesivir in Japan, there are no approved therapeutics options for the treatment
Finalists 2020
Harnessing the Power of Together. by Hanover Communications. for Chugai.
Data provided by GlobalData
GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.
To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE's Top Pharma List - Methodology
COVID-19 Updates and Daily News
Featured jobs
- Imperial College London to lead major coronavirus home testing programme
- ViiV takes on Gilead’s PReP dominance with HIV injectable data
- Moderna’s coronavirus vaccine hits first objectives
- Roche says antibody test for COVID-19 should be ready in May
- AZ secures capacity for one billion coronavirus vaccine doses
- UK’s new COVID-19 trial initiative fast-tracks BerGenBio’s bemcentinib
- AZ secures capacity for one billion coronavirus vaccine doses
- EMA starts review of MorphoSys’ tafasitamab for lymphoma
- Gilead, Galapagos dip on mixed ulcerative colitis data
- Roche makes protein degradation play with $135m Vividion deal
- Octapharma cleared to start phase 3 trial of Octagam in COVID-19
- UK government expands coronavirus testing criteria
PMHub
Blue Latitude Health
Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...
Latest intelligence
- OPEN Health attend EB World Congress—building on momentum and strength in numbers for epidermolysis bullosa
- Ben Speller shares his thoughts on the value of disease specific congresses...
- OPEN Health use PR to support clinical trial recruitment
- International Clinical Trials Day finds clinical research in the spotlight like never before, with any news coming from the many studies into potential vaccines and treatments for SARS-CoV-2...
- Covid-19: what could it mean for the diabetic population?
- Steve How and Oli Hudson, of Wilmington Healthcare, assess the scale of the diabetes crisis and how coronavirus might impact on it...
Quick links
Infographics
